Biocon Says medical science Eased Psoriasis in Late-Stage Trial BusinessWeek 9 (Bloomberg) -- Biocon Ltd. aforementioned its experimental drug itolizumab met the main content of a late-stage clinical trial, reducing the intensity of psoriasis . AN interim analysis of the 200-person study showed that patients taking the drug had a response ... Biocon Announces Positive effectiveness Data with its new Monoclonal Antibody ... MarketWatch (press release) all xv news articles » Link To Article
No comments:
Post a Comment